Westlake Epoxy Expands Distribution Relationship with Brenntag to India
18.2.2026 03:30:00 EET | Business Wire | Press release
Westlake Corporation (NYSE: WLK) today announced that Westlake Epoxy will expand its long‑standing distribution relationship with Brenntag to South and West India. The agreement builds on a successful collaboration across Europe, North and South America, and Southeast Asia, extending Westlake Epoxy’s reach into one of the world’s fastest‑growing coatings, adhesives and construction markets.
Under the expanded collaboration, Brenntag will distribute Westlake Epoxy’s established portfolio of epoxy solutions for coatings, adhesives and construction applications, including the EPON™, EPIKOTE™, EPIKURE™ and EPI‑REZ™ product lines. Customers are expected to benefit from reliable local supply, technical service and application‑focused formulation support tailored to regional requirements.
India’s coatings, adhesives and construction sectors continue to grow, driven by infrastructure investment, urbanization and increasing performance expectations. By combining Westlake Epoxy’s proven epoxy technologies with Brenntag’s regional presence and technical capabilities, the collaboration strengthens support for customers addressing evolving performance, processing and regulatory needs.
“Expanding our collaboration with Brenntag into India allows us to support customers more closely in a high‑growth market,” said Brian Powers, Vice President, Westlake Epoxy. “Brenntag’s deep market understanding, technical expertise and strong customer reach makes them a strong partner for the Indian market. This collaboration enables us to serve customers more closely and respond effectively to local application and performance requirements.”
“With our presence in South and West India and strong technical capabilities, we are well positioned to support customers with tailored epoxy solutions for coatings, adhesives and construction, while Westlake Epoxy’s reliable, portfolio supports further business growth,” said Sanjay Karkhanis, Regional President, Material Science Brenntag APAC. “The expansion of our collaboration with Westlake Epoxy into India strengthens our Material Science offering in a fast-growing market.”
About Westlake Epoxy
Westlake Epoxy, a Westlake company, is a global leader in epoxy resins, curing agents and specialty systems for higher‑performance materials, coatings and composites, delivering strength, durability, chemical and corrosion resistance, and stronger adhesion performance in demanding applications. The EpoVIVE™ portfolio of epoxy phenolic resins and curing agents reflects Westlake Epoxy’s dedication to reducing the environmental impact of its products. Serving industries such as coatings, construction, adhesives, automotive, civil engineering, composites, electronics and renewable energy, Westlake Epoxy supports customers worldwide with advanced materials and application expertise. For more information, visit Frontpage | Westlakeepoxy or contact epoxyservice@westlake.com
About Westlake
Westlake Corporation (NYSE: WLK) is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe, and North America, we provide building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the company's web site at www.westlake.com.
About Brenntag
Brenntag is the global market leader in chemicals and ingredients distribution, connecting customers and suppliers worldwide. Headquartered in Essen, Germany, it has over 18,100 employees at around 600 sites in more than 70 countries. Through its two divisions, Brenntag Essentials and Brenntag Specialties, the company offers a broad portfolio of chemicals and ingredients plus tailored technical, regulatory, supply chain, and digital solutions, and it is committed to an ambitious sustainability agenda. For more information, visit www.brenntag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260217333584/en/
Contacts
Media contact:
Dr. Oliver Mieden,
Westlake Germany GmbH & Co. KG,
Phone: +49 (0)89 96103-282, E-mail: media@westlake.com
Mila Hierner,
Westlake Epoxy Belgium BV,
Phone: +32 10 48 22 50, E-mail: media@westlake.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom